Solid phase extraction and high-performance liquid chromatographic determination of lazertinib in human plasma
{{output}}
Lazertinib is a novel third-generation tyrosine kinase inhibitor (TKI) developed for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Reports on previous EGFR-TKIs have detailed significant associations betwee... ...
